middle.news
Immutep Hits 50% Enrolment in Pivotal Lung Cancer Trial
8:32am on Friday 6th of February, 2026 AEDT
•
Healthcare
Read Story
Immutep Hits 50% Enrolment in Pivotal Lung Cancer Trial
8:32am on Friday 6th of February, 2026 AEDT
Key Points
50% enrolment achieved in global Phase III TACTI-004 trial
Trial evaluates eftilagimod alfa with KEYTRUDA and chemotherapy in 1L NSCLC
Futility analysis expected in Q1 2026; enrolment completion targeted for Q3 2026
Over 140 clinical sites activated across 27 countries
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE